(Q34219107)

31 July 2017

1 reference

title

Mood disorders associated with interferon treatment: theoretical and practical considerations (English)

1 reference

31 July 2017

1 reference

P Malek-Ahmadi

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

Annals of Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

35

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

489-495

1 reference

Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration

31 July 2017

cites work

1 reference

Human recombinant tumor necrosis factor and interferon affect the activity of neurons in the organum vasculosum laminae terminalis

21 January 2018

1 reference

Alpha-interferon modifies cortical EEG activity: dose-dependence and antagonism by naloxone

21 January 2018

1 reference

Effects of interferon alpha on performance in man: a preliminary report

21 January 2018

1 reference

Central nervous system toxicity of interferon

21 January 2018

1 reference

Hepatitis C, interferon alfa, and depression

21 January 2018

1 reference

Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review

21 January 2018

1 reference

Side effects of α interferon in chronic hepatitis C

21 January 2018

1 reference

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer

21 January 2018

1 reference

Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.

21 January 2018

1 reference

Psychiatric complications of long-term interferon alfa therapy

21 January 2018

1 reference

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

The treatment of chronic viral hepatitis

21 January 2018

1 reference

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

21 January 2018

1 reference

Management of multiple sclerosis

21 January 2018

1 reference

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b.

21 January 2018

1 reference

Side effects of alpha interferon

21 January 2018

1 reference

Burns in a suicide attempt related to psychiatric side effects of interferon

21 January 2018

1 reference

More on the depressive effects of interferon alfa

21 January 2018

1 reference

Neuropsychiatric toxicity associated with cytokine therapies

21 January 2018

1 reference

Persistent neurotoxicity of systemically administered interferon-alpha

21 January 2018

1 reference

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia

21 January 2018

1 reference

Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities.

21 January 2018

1 reference

Bipolar disorder associated with interferon-alpha treatment

21 January 2018

1 reference

A phase I study of human natural interferon-beta in cancer patients

21 January 2018

1 reference

The macrophage theory of depression

21 January 2018

1 reference

The monocyte-T-lymphocyte hypothesis of major depression

21 January 2018

1 reference

Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan

21 January 2018

1 reference

Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter

21 January 2018

1 reference

Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response

21 January 2018

1 reference

Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life

21 January 2018

1 reference

Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial

21 January 2018

1 reference

Neuropsychological effects of Interferon Alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals.

21 January 2018

1 reference

Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

21 January 2018

1 reference

Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C.

21 January 2018

1 reference

Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions

21 January 2018

1 reference

Depression associated with multiple sclerosis: an etiological conundrum

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.10172

1 reference

31 July 2017

1 reference